{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:52:37Z","timestamp":1793213557105,"version":"4.5.0"},"posted":{"date-parts":[[2024,8,28]]},"group-title":"Epidemiology","reference-count":38,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>long<\/jats:title>\n                  <jats:p>\n                    The introduction of artemisinin combination therapies (ACTs) has significantly reduced the burden of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria, yet the emergence of artemisinin partial resistance (ART-R) as well as partner drug resistance threatens these gains. Recent confirmations of prevalent\n                    <jats:italic>de novo<\/jats:italic>\n                    ART-R mutations in Africa, in particular in Rwanda, Uganda and Ethiopia, underscore the urgency of addressing this issue in Africa. Our objective is to characterise this evolving resistance landscape in Africa and understand the speed with which ART-R will continue to spread. We produce estimates of both ART-R and partner drug resistance by bringing together WHO, WWARN and MalariaGen Pf7k data on antimalarial resistance in combination with a literature review. We integrate these estimates within a mathematical modelling approach, aincorporating to estimate parameters known to impact the selection of ART-R for each malaria-endemic country and explore scenarios of ART-R spread and establishment. We identify 16 malaria-endemic countries in Africa to prioritise for surveillance and future deployment of alternative antimalarial strategies, based on ART-R reaching greater than 10% prevalence by 2040 under current malaria burden and effective-treatment coverage. If resistance continues to spread at current rates with no change in drug policy, we predict that partner drug resistance will emerge and the mean percentage of treatment failure across Africa will reach 30.74% by 2060 (parameter uncertainty range: 24.98% - 34.54%). This translates to an alarming number of treatment failures, with 52,980,600 absolute cases of treatment failure predicted in 2060 in Africa (parameter uncertainty range: 26,374,200 - 93,672,400) based on current effective treatment coverage. Our results provide a refined and updated prediction model for the emergence of ART-R to help guide antimalarial policy and prioritise future surveillance efforts and innovation in Africa. These results put into stark context the speed with which antimalarial resistance may spread in Africa if left unchecked, confirming the need for swift and decisive action in formulating antimalarial treatment policies focused on furthering malaria control and containing antimalarial resistance in Africa.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>short<\/jats:title>\n                  <jats:p>\n                    The rise of artemisinin partial resistance (ART-R) and increasing partner drug tolerance by\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria in Africa threatens to undo malaria control efforts. Recent confirmations of de novo ART-R markers in Rwanda, Uganda, and Ethiopia highlight the urgent need to address this threat in Africa, where the vast majority of cases and deaths occur. This study characterises the resistance landscape and predicts the spread of antimalarial resistance across Africa. We estimate and map the current levels of resistance markers related to artesmisinin and its partner drugs using WHO, WWARN, and MalariaGen Pf7k data. We combine these estimates with current malaria transmission and treatment data and use an established individual-based model of malaria resistance to simulate future resistance spread. We identify 16 African countries at highest risk of ART-R for prioritisation of enhanced surveillance and alternative antimalarial strategies. We project that, without policy changes, ART-R will exceed 10% in these regions by 2040. By 2060, if resistance spreads unchecked, we predict mean treatment failure rates will reach 30.74% (parameter uncertainty range: 24.98% - 34.54%) across Africa. This alarming spread of resistance is predicted to cause 52.98 million treatment failures (uncertainty range: 26.37 million - 93.67 million) in 2060. The impact of antimalarial resistance in Africa, if left unchecked, would hugely damage efforts to reduce malaria burden. Our results underscore the critical need for swift policy action to contain resistance and guide future surveillance and intervention efforts.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.08.28.24312699","type":"posted-content","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:20:12Z","timestamp":1724887212000},"source":"Crossref","is-referenced-by-count":7,"title":["Risk of selection and timelines for the continued spread of artemisinin and partner drug resistance in Africa"],"prefix":"10.64898","author":[{"given":"Oliver J.","family":"Watson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Muchiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Meier-Sherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Asua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Katairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Cuomo-Dannenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Winskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Okell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Scudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Woolsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024083106450623000_2024.08.28.24312699v1.1","unstructured":"World Health Organization. Guidelines for the treatment of malaria, 1st edition. 2006 http:\/\/www.who.int\/iris\/handle\/10665\/149822."},{"key":"2024083106450623000_2024.08.28.24312699v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12876"},{"key":"2024083106450623000_2024.08.28.24312699v1.3","doi-asserted-by":"crossref","unstructured":"Uwimana A , Legrand E , Stokes BH , Ndikumana JLM. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med 2020. https:\/\/www.nature.com\/articles\/s41591-020-1005-2.","DOI":"10.1038\/s41591-020-1005-2"},{"key":"2024083106450623000_2024.08.28.24312699v1.4","doi-asserted-by":"crossref","unstructured":"Conrad MD , Asua V , Garg S . Evolution of partial resistance to artemisinins in malaria parasites in Uganda. England Journal of \u2026 2023. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2211803.","DOI":"10.1056\/NEJMoa2211803"},{"key":"2024083106450623000_2024.08.28.24312699v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00141-5"},{"key":"2024083106450623000_2024.08.28.24312699v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02551-w"},{"key":"2024083106450623000_2024.08.28.24312699v1.7","unstructured":"Geneva: World Health Organization. Strategy to respond to antimalarial drug resistance in Africa. 2022 https:\/\/www.who.int\/news\/item\/18-11-2022-tackling-emerging-antimalarial-drug-resistance-in-africa (accessed April 24, 2024)."},{"key":"2024083106450623000_2024.08.28.24312699v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30391-3"},{"key":"2024083106450623000_2024.08.28.24312699v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2005.04.003"},{"key":"2024083106450623000_2024.08.28.24312699v1.10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/trstmh\/trz009","article-title":"Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial","volume":"113","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024083106450623000_2024.08.28.24312699v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taad159"},{"key":"2024083106450623000_2024.08.28.24312699v1.12","first-page":"445","article-title":"Treatment failure in a UK malaria patient harboring genetically variant Plasmodium falciparum from Uganda with reduced in vitro susceptibility to artemisinin and lumefantrine","volume":"78","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024083106450623000_2024.08.28.24312699v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01352-3"},{"key":"2024083106450623000_2024.08.28.24312699v1.14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/cid\/ciac527","article-title":"Malaria Transmission Dynamics in a High-Transmission Setting of Western Kenya and the Inadequate Treatment Response to Artemether-Lumefantrine in an Asymptomatic Population","volume":"76","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024083106450623000_2024.08.28.24312699v1.15","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0843-8"},{"key":"2024083106450623000_2024.08.28.24312699v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu358"},{"key":"2024083106450623000_2024.08.28.24312699v1.17","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.03.24302209"},{"key":"2024083106450623000_2024.08.28.24312699v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(15)00162-X"},{"key":"2024083106450623000_2024.08.28.24312699v1.19","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/S2666-5247(22)00155-0","article-title":"Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study","volume":"3","year":"2022","journal-title":"Lancet Microbe"},{"key":"2024083106450623000_2024.08.28.24312699v1.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2100685118"},{"key":"2024083106450623000_2024.08.28.24312699v1.21","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1962291"},{"key":"2024083106450623000_2024.08.28.24312699v1.22","doi-asserted-by":"publisher","DOI":"10.3389\/fepid.2022.1041896"},{"key":"2024083106450623000_2024.08.28.24312699v1.23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/molbev\/msaa225","article-title":"Evaluating the Performance of Malaria Genetics for Inferring Changes in Transmission Intensity Using Transmission Modeling","volume":"38","year":"2021","journal-title":"Mol Biol Evol"},{"key":"2024083106450623000_2024.08.28.24312699v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4136"},{"key":"2024083106450623000_2024.08.28.24312699v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30169-4"},{"key":"2024083106450623000_2024.08.28.24312699v1.26","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1111\/eva.13077","article-title":"Incorporating genetic selection into individual-based models of malaria and other infectious diseases","volume":"13","year":"2020","journal-title":"Evol Appl"},{"key":"2024083106450623000_2024.08.28.24312699v1.27","unstructured":"World Health Organization. Malaria Threat Maps. 2017. http:\/\/apps.who.int\/malaria\/maps\/threats\/ (accessed June 20, 2023)."},{"key":"2024083106450623000_2024.08.28.24312699v1.28","unstructured":"WorldWide Antimalarial Research Network (WWARN). WWARN Explorer. http:\/\/www.wwarn.org\/tracking-resistance\/wwarn-explorer."},{"key":"2024083106450623000_2024.08.28.24312699v1.29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.12688\/wellcomeopenres.18681.1","article-title":"Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples","volume":"8","author":"MalariaGEN,","year":"2023","journal-title":"Wellcome Open Res"},{"key":"2024083106450623000_2024.08.28.24312699v1.30","doi-asserted-by":"crossref","first-page":"e0002200","DOI":"10.1371\/journal.pgph.0002200","article-title":"Antimalarial mass drug administration in large populations and the evolution of drug resistance","volume":"3","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"2024083106450623000_2024.08.28.24312699v1.31","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s41467-020-15779-8","article-title":"The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2024083106450623000_2024.08.28.24312699v1.32","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2024, Online Edition. 2024."},{"key":"2024083106450623000_2024.08.28.24312699v1.33","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed4010026"},{"key":"2024083106450623000_2024.08.28.24312699v1.34","doi-asserted-by":"crossref","unstructured":"Bretscher MT , Dahal P , Griffin J , et al. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Med 2020; 18: 47.","DOI":"10.1186\/s12916-020-1494-3"},{"key":"2024083106450623000_2024.08.28.24312699v1.35","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12349"},{"key":"2024083106450623000_2024.08.28.24312699v1.36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.20010"},{"key":"2024083106450623000_2024.08.28.24312699v1.37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1473-3099(23)00209-8","article-title":"Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial","volume":"23","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024083106450623000_2024.08.28.24312699v1.38","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","article-title":"Preventing antimalarial drug resistance with triple artemisinin-based combination therapies","volume":"14","year":"2023","journal-title":"Nat Commun"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.28.24312699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:10:29Z","timestamp":1768507829000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.08.28.24312699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1101\/2024.08.28.24312699","relation":{},"subject":[],"published":{"date-parts":[[2024,8,28]]},"subtype":"preprint"}}